Production and Characterization of New Anti-HER2 Monoclonal Antibodies

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

Volumn 34, Issue 3, 2015, Pages 213-221

  Mahdavi, Manijeh ^a   Keyhanfar, Mehrnaz ^b   Jafarian, Abbas ^a   Mohabatkar, Hassan ^b   Rabbani, Mohammad ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF ISFAHAN   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CANCER VACCINE; CHIMERIC PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPITOPE; HER2 MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CANCER CELL; CANCER THERAPY; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE SYSTEM; IMMUNOASSAY; IMMUNOFLUORESCENCE; MOUSE; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SUPERNATANT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BREAST NEOPLASMS; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOLOGY; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 84932118670     PISSN: None     EISSN: 21679436     Source Type: Journal    
DOI: 10.1089/mab.2014.0092     Document Type: Article

References (44)

1. Breast cancer epidemiology. Medical News. http://www.news-medical.net/health/Breast-Cancer-Epidemiology.aspx
2. Breast cancer incidence statistics. Cancer Research UK. http://www.cancerresearchuk.org/cancerinfo/cancerstats/types/breast/incidence/uk-breast-cancer-incidence-statistics
3. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, and Caan BJ: Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 2009;11:R31-44.
4. Breast cancer statistics. Cancer Australia. http://canceraustralia.gov.au/affected-cancer/cancer-types/breast-cancer/breast-cancer-statistics
5. Kolahdoozan S, Sadjadi A, Radmard AR, and Khademi H: Five common cancers in Iran [minireview]. Arch Iran Med 2010;13(2):143-146.
6. Hashemian M, Ghardashi F, Asadi Z, Khosroabadi A, Pejhan A, Javan R, and Nakhaei MR: Incidence and screening of breast cancer in Iranian women. Life Sci J 2013;10(9s):361-366.
7. Faltus T: Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia 2004;6(6):786-795.
8. Yang G: Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem 2004;279(6):4339-4345.
9. Pils D: In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. Br J Cancer 2007;96(3):485-491.
10. Shawver LK, Slamon D, and Ullrich A: Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002;1(2):117-123.
11. Roh H, Pippin J, and Drebin JA: Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. Cancer Res 2000;60(3):560-565.
12. Tai W, Qin B, and Cheng K: Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF. Mol Pharm 2010;7(2):543-556.
13. FDA: FDA approves Perjeta for neoadjuvant breast cancer treatment. U.S. Food and Drug Administration. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm370393.htm
14. Tai W, Mahato R, and Cheng K: The role of HER2 in cancer therapy and targeted drug delivery [review]. J Cont Rel 2010;146:264-275.
15. Rubin I, and Yarden Y: The basic biology of HER2. Ann Oncol 2001;12(Suppl 1)S3-S8.
16. Lax I: Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol Cell Biol 1988;8(4):1831-1834.
17. Pietras RJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10(12):2435-2446.
18. Di Fiore PP: ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987;237(4811):178-182.
19. Garrett JT, Kaumaya P, Pei D, and Dalbey R: Peptide based B cell epitope vaccines targeting HER-2/Neu. 2007. Dissertation, Ohio State University.
20. Jones A, and Kaumaya P: Peptide vaccines against the HER-2/neu dimerization loop. 2006. Dissertation, Ohio State University.
21. Calabrich A, Fernandes GS, and Katz A: Trastuzumab: mechanisms of resistance and therapeutic opportunities. Oncology 2008;22:1250-1258.
22. Nahta R: Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3(5):269-280.
23. Cameron DA, and Stein S: Drug insight: intracellular inhibitors of HER2-clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol 2008;5(9):512-520.
24. Agus DB: Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23(11):2534-2543.
25. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, and Pisacane PI: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-137.
26. Nahta R, Hung MC, and Esteva FJ: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64(7):2343-2346.
27. Scheuer W: Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009;69(24):9330-9336.
28. Zhang AL, Xue H, Ling XG, and Gao Y: Anti-HER-2engineering antibody ChA21 inhibits growth and induces apoptosis of SK-OV-3 cells. J Exp Clin Cancer Res 2010;29:23-32.
29. Ishida T, Tsujisaki M, Hinoda Y, Imai K, and Yachi A: Establishment and characterization of mouse-human chimeric mab to erbB-2 product. Jpn J Cancer Res 1994;85:172-178.
30. Wang JN, Feng JN, Yua M, Xua M, Shi M, and Zhou T: Structural analyses of the epitopes on erbB2 interacted with inhibitory or non-inhibitor monoclonal antibodies. Mol Immunol 2004;40;963-969.
31. Mahdavi M, Mohabatkar H, Keyhanfar M, Jafarian Dehkordi A, and Rabbani M: Linear and conformational B cell epitope prediction of HER 2 ECD-subdomain III by in silico methods. Asian Pac J Cancer Prev 2012;13:3053-3059.
32. Mahdavi M, Keyhanfar M, Moreau V, Mohabatkar H, and Rabbani M: In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines. Asian Pac J Cancer Prev 2013;14:5973-5981.
33. Goede A, Jaeger IS, and Preissner R: SUPERFICIAL-surface mapping of proteins via structure-based peptide library design. BMC Bioinform 2005;6:223-230.
34. Moreau V, Fleury C, and Piquer D: PEPOP: computational design of immunogenic peptides. BMC Bioinform 2008;9:71-86.
35. Mahdavi M, Jafarian A, Keyhanfar M, Mohabbatkar H, and Rabbani M: Immunization with a novel peptide vaccine representing B and T-cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer. Tumor Biol 2014;35:12049-12057.
36. Flies DB, and Chen L: A simple and rapid vortex method for preparing antigen/adjuvant emulsions for immunization. J Immunol Methods 2003;276:239-242.
37. Yokoyama WM: Production of monoclonal antibodies. In: Current Protocols in Immunology. John Wiley & Sons, New York, 1995.
38. Tabll A, Khalil SB, El-Shenawy RM, and Esmat G: Establishment of hybrid cell lines producing monoclonal antibodies to a synthetic peptide from the E1 region of the hepatitis C virus. J Immunoassay Immunochem 2007;29:91-104.
39. Hornbeck P: Enzyme-linked immunosorbent assays. In: Current Protocols in Immunology. John Wiley & Sons, New York, 1991.
40. Roche lab techniques. http://www.roche-applied-science.com/
41. Dakappagari NK, Douglas DB, Triozzi PL, and Stevens VC: Prevention of mammary tumours with a chimeric Her-2 B-cell epitope peptide vaccine. Cancer Res 2000;60:3782-3789.
42. Axelsena TV, Holma A, Christiansena G, and Birkelund S: Identification of the shortest AB-peptide generating highly specific antibodies against the C-terminal end of amyloid-B42. Vaccine 2011;29:3260-3269.
43. Dakappagari NK, Pyles J, Parihar R, and Carson WE: Multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumour responses. J Immunol 2003;170:4242-4253.
44. Wang B, Kaumaya PTP, and Cohn DE: Immunization with synthetic VEGF peptides in ovarian cancer. Gyn Oncol 2010;119:564-570.